Neuphoria Therapeutics Inc (NASDAQ:NEUP) — Market Cap & Net Worth
Market Cap & Net Worth: Neuphoria Therapeutics Inc (NEUP)
Neuphoria Therapeutics Inc (NASDAQ:NEUP) has a market capitalization of $20.27 Million ($20.27 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25156 globally and #5329 in its home market, demonstrating a 1.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neuphoria Therapeutics Inc's stock price $3.80 by its total outstanding shares 5404551 (5.40 Million). Also see NEUP asset base for a full breakdown of the balance sheet.
Neuphoria Therapeutics Inc Market Cap History: 2024 to 2026
Neuphoria Therapeutics Inc's market capitalization history from 2024 to 2026. Data shows change from $18.54 Million to $20.54 Million (-4.46% CAGR). Also see NEUP operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Neuphoria Therapeutics Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #715 of 976 |
Weight: Neuphoria Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Neuphoria Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neuphoria Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Neuphoria Therapeutics Inc share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.34x
Neuphoria Therapeutics Inc's market cap is 1.34 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $20.97 Million | $15.65 Million | -$369.63K | 1.34x | N/A |
Competitor Companies of NEUP by Market Capitalization
Companies near Neuphoria Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review NEUP goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Neuphoria Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Neuphoria Therapeutics Inc Historical Marketcap From 2024 to 2026
Between 2024 and today, Neuphoria Therapeutics Inc's market cap moved from $18.54 Million to $ 20.54 Million, with a yearly change of -4.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $20.54 Million | -2.06% |
| 2025 | $20.97 Million | +13.12% |
| 2024 | $18.54 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Neuphoria Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $20.27 Million USD |
| MoneyControl | $20.27 Million USD |
| MarketWatch | $20.27 Million USD |
| marketcap.company | $20.27 Million USD |
| Reuters | $20.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disord… Read more